https://www.selleckchem.com/pr....oducts/mivebresib-ab
2 months and median overall survival of 10.3 months. Compared with cohorts 1, 2, and 4 combined, cohort 3 had lower frequency of some Rova-T-related adverse events of special interest, such as pleural effusion (0 versus 33%), pericardial effusion (0 versus 17%), ascites (0 versus 8%), peripheral edema (36% versus 42%), generalized edema (0 versus 8%), pneumonia (7% versus 25%), and hypoalbuminemia (0 versus 17%). Lower Rova-T doses may be associated with lower incidence of some Rova-T-related adverse events of special intere
Like
Comment
Share
